Prostate Cancer ADT Has Fewer Cardiovascular Risks Than Expected
Investigators found that men receiving androgen deprivation therapy for prostate cancer had a 1% rate of major adverse cardiovascular events.
Prostate Cancer
Abiraterone Acetate + Prednisone Cuts Metastasis in Prostate Cancer
And standard of care plus abiraterone improves survival in men with metastatic castration-sensitive prostate cancer
Enzalutamide Plus ADT Prolongs Survival in Metastatic Hormone-Sensitive Prostate Cancer
Enzalutamide plus androgen deprivation therapy improved overall survival by 34%.
Apalutamide Prolongs Survival in mCSPC Regardless of Disease Volume
A final analysis of the TITAN trial shows that apalutamide vs placebo added to ADT significantly lowers the risk of death and castration-resistant disease in men with metastatic castration-sensitive prostate cancer.
Metformin Possibly Beneficial in Advanced Prostate Cancer
In a randomized controlled study, adding metformin to androgen deprivation therapy for low-tumor-volume metastatic hormone-sensitive prostate cancer significantly delayed development of castration-resistant disease.
Prostate Cancer ADT Not Linked to Greater Cardiovascular Mortality
Androgen deprivation therapy added to radiation therapy (RT) for unfavorable-risk prostate cancer is not associated with an increased risk for cardiovascular mortality compared with RT alone, even among patients with preexisting cardiovascular disease, a study found.
Camcevi Approved for Advanced Prostate Cancer
The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Camcevi in 137 adults with advanced prostate cancer.
Pylarify, a PSMA-Targeted PET Imaging Agent, Approved for Prostate Cancer Detection
The approval was based on data from the phase 2/3 OSPREY and phase 3 CONDOR trials that evaluated the diagnostic performance and safety of Pylarify injection.
Nonmetastatic CRPC Treatments Compared for Efficacy and Safety
Investigators compared the efficacy, safety, and costs of abiraterone, darolutamide, enzalutamide, and apalutamide in treating nmCRPC.
Men on Active Surveillance for Prostate CA May Benefit From 5-ARI Use
Men who take 5-alpha-reductase inhibitors while on active surveillance for prostate cancer are less likely to experience cancer progression, according to a new study
